Priya Tiwari

Medical Oncologist

[Annals of Oncology @Annals_Oncology]

🆕editorial in press: PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block? @Al3ssandroRusso
https://t.co/87BSVR0CHh

[Priya Tiwari @Priya1111]

Very important

[Yakup Ergün @dr_yakupergun]

Adding RT to SOX after D2 gastrectomy failed to improve DFS or OS—another nail in the coffin for routine adjuvant radiotherapy.

https://t.co/uKTYij82Gp

[Dr Amol Akhade @SuyogCancer]

We have excellent webinar today on GU updates from ASCO 2026.
It was well attended by over 145 oncologist .
I thank all my faculty for taking time out from their busy schedules .
I learned a lot from this discussion. I hope it was useful for all those who attended it . #OncoWisdom
Thank you @sonpavde @gbanna74 @yekeduz_emre @DVAraujoMD
@VanitaNoronha @Priya1111 @DrUddiGoswami @OncBrothers @oncodaily

[Arndt Vogel @ArndtVogel]

Outcomes of Y90-radioembolization as downstaging to liver transplantation HCC and tumoral portal vein thrombosis
@HEP_Journal
https://t.co/RcHl1K7vxQ
👉25% sustained downstaging after TARE
👉15% eventually LTx with good outcome
🧐Downstaging is feasible in MVI pts
@myESMO @ILCAnews @EASLnews

[Arndt Vogel @ArndtVogel]

🔥off the press🔥
Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Phase 3 RASolute 302 inMetastatic Pancreatic Cancer
👉mOS 13.2 vs 6.7 mo; HR:0.40 (p < 0.0001)
👏finally a significant benefit in PDAC, looking forward to 1st line studies
@myESMO @ASCOPost

[Priya Tiwari @Priya1111]

Promising !

[Anirban Maitra @Aiims1742]

🚨🚨🚨
RASOLUTE-302 Ph3 is POSITIVE
"Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW!

AMAZING news for patients with #PancreaticCancer
The RAS Revolution is ON!!
https://t.co/I59NNWRB1O

[Priya Tiwari @Priya1111]

Interesting

[Erman Akkus @Erman_Akkus]

🟠Is adjuvant IO story over in HCC❓

➡️Our meta-analysis has been published in JGH
✅IO-based adjuvant vs surveillance
RFS, HR: 0.51, (0.44–0.60), p < 0.001
🚨Data is mainly from China and retrospective
✅In line with the recent letter published in JHEP (https://t.co/ZPN0GJtHMr)

❗️Patient selection may be the key
🤔Do clinical trials reflect the real-life complexity and heterogeneity of HCC?

👉https://t.co/Z4c4DMuRGT

#cancer #oncology #liver #MedX @OncoAlert

[Arndt Vogel @ArndtVogel]

Disruptive Analysis of Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Clinical and Therapeutic Distinctions Between Lowand Mid-Rectal Cancers
@JCO_ASCO
https://t.co/6TR40TcejX
👏excellent review
👉Adopting a location-specific, patient-centered approach is key
@myESMO @ASCO

[JAMA @JAMA_current]

The European Society of Gynaecological Oncology consensus statements published in JAMA support opportunistic salpingectomy as a preventive measure against tubo-ovarian carcinoma, safe and feasible during pelvic or abdominal surgery.

🎥 Watch the video and learn more: https://t.co/BjCLpllQZE

[Priya Tiwari @Priya1111]

Makes sense !

[Karamvir Yadav @K_Yadavir]

Very interesting article @JCO_ASCO
A good oncologist is not defined by chemotherapy alone.

Patient-centered.
Emotionally intelligent.
Ethically grounded.
Lifelong learner.

203 JCO narratives distilled into 7 defining themes.

Excellence = science + soul.

#Oncology #MedicalEducation @OncoAlert @OncBrothers @oncodaily

[Ravi Mehrotra, MD (Prevent Cancer) @StopCancerDoc]

DYK: The Indian government is rolling out a massive nationwide campaign to provide the HPV (Human Papillomavirus) vaccine for free, targeting cervical cancer—the second most common cancer among women in the country.

Here is the breakdown of what this 90-day "mega drive" looks like:

Key Details of the Drive
Target Group: Specifically, girls aged 14 years. This age was chosen because the vaccine is most effective when administered before exposure to the virus, and the immune response is particularly robust in this group.

The Vaccine: The government is using Gardasil 4 (a quadrivalent vaccine), which protects against the four most common strains of HPV (6, 11, 16, and 18).

The Supply: 2.6 crore doses have been secured through a partnership with Gavi, the Vaccine Alliance, ensuring a steady supply for the next two years.

Single-Dose Strategy: In line with updated WHO recommendations, India is opting for a single-shot schedule, which scientific evidence shows provides durable protection for girls in this age bracket.

How to Get the Shot
The rollout is expected to begin in the first week of March 2026.

Where: Available free of cost at government health facilities, including Ayushman Arogya Mandirs (Primary Health Centres), Community Health Centres, and District Hospitals.

Registration: Parents and guardians can book appointments through the U-WIN portal (similar to the Co-WIN system used during the pandemic).

Voluntary: While highly encouraged, the vaccination is voluntary.

This is a huge step toward the goal of eliminating cervical cancer in India, potentially saving tens of thousands of lives every year. @SumiSukanya carries my quotes in @IndiaToday

https://t.co/rtoxlaPG2m

[Priya Tiwari @Priya1111]

Capox is the boss!

[Arndt Vogel @ArndtVogel]

3 vs 6 mo of Adjuvant FOLFOX for CRC: Final Results of SCOT Phase III, Noninferiority Trial
@JCO_ASCO
https://t.co/NKoVaSy3Gw
👉5yr OS for 3 vs 6 months 82.4% in both groups
👉noninferiority shown for CAPOX but not for FOLFOX
👉significantly less tox
🧐3 months should be recommended for most pts
@myESMO @ASCO

[Priya Tiwari @Priya1111]

Useful

[Arndt Vogel @ArndtVogel]

LyRICX trial: Liposomal irinotecan, carboplatin or oxaliplatin with or without nivolumab in the 1st line GC/GEJC: A randomized phase 2 study
👉Much less tox with CapCar vs CapOx with similar PFS
🧐CapCar appears to be a valid option in 1st line
@myesmo @ASCO

[The Khel India @TheKhelIndia]

INDIA ARE THE WORLD CUP CHAMPIONS 🏆

- Wins First Ever Squash World Cup in History! 🥹

[Dr Akhil Santhosh MD DM MRCP(UK) @tuttsakhil]

Clinical overview of trophoblast surface antigen 2 Antibody-Drug conjugates in Non–Small cell lung cancer - @myESMO https://t.co/NfYsP7OsVX

[Narendra Modi @narendramodi]

Congratulations to our Indian Women’s Kabaddi Team for making the nation proud by winning the Kabaddi World Cup 2025! They have showcased outstanding grit, skills and dedication. Their victory will inspire countless youngsters to pursue Kabaddi, dream bigger and aim higher.

[Priya Tiwari @Priya1111]

Congrats!

[The Khel India @TheKhelIndia]

LAKSHYA SEN IS AUSTRALIA OPEN CHAMPION🏆

[Priya Tiwari @Priya1111]

Yes

[Vivek Subbiah, MD @VivekSubbiah]

If Exercise Were a Pill, We'd All Prescribe It to Patients With Cancer. But It's Not | Journal of Clinical Oncology https://t.co/tofgbuAeCJ

[Dr Rishabh Jain @DrRishabhOnco]

How long should ADT really be with definitive RT

🚨 NEW JAMA ONCOLOGY META-ANALYSIS
10,266 pts • 13 RCTs • MARCAP IPD

🎯 Key Finding :

📉 Benefit rises rapidly up to ~12 months
🛑 After 12 months → benefit plateaus
⚠️ But OCM (non–prostate cancer deaths) steadily increases with longer ADT
➡️ So the “longer is better” rule is NOT universally true.

🧬 Optimal ADT Duration (by 10-year DM + NNT curves):
🟦 1 intermediate-risk factor: 0 months
🟩 ≥2 intermediate-risk factors: 6 months
🟧 NCCN high-risk: 12 months
🔴 Very high-risk: No clear plateau - prolonged ADT still beneficial

🧠 Clinical Interpretation:
•IR → Short-term ADT is enough
•High-risk → 12 months is the sweet spot
•Very high-risk → Consider long-term ADT

Always balance:
✅ PCSM ↓
❌ OCM ↑ with duration
🎯 Life expectancy + comorbidities + patient preference

📖 Full reference in comment ⬇️
#OncoTwitter #MedTwitter #RadiationOncology #ProstateCancer @OncoAlert @myesmo @esmo_open @ASCO

[Priya Tiwari @Priya1111]

Remarkable

[Eric Topol @EricTopol]

“I had hemophilia for nearly five decades. I went to Philadelphia and had a 45-minute infusion, and my hemophilia was gone.”
Genes-&gt; Medicine @NatureMedicine
https://t.co/WLWMQtUj31